100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R44NS108869
Award Date
9/30/18
Completion Date
8/31/24
Dollars Obligated
$5.7M
Overview
Activity
8
Transactions
8
Subawards
Similar Awards
Federal Agency
National Institute of Neurological Disorders and Stroke
Awardee
Axonova Medical Inc. (DLUMA6JAZ1K4)
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Update #1
Update #2
GENERATION OF TISSUE ENGINEERED NERVE GRAFTS FROM GALSAFE PORCINE NEURONS
Posted 9/23/20
5
1
2
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
GENERATION OF TISSUE ENGINEERED NERVE GRAFTS FROM GALSAFE PORCINE NEURONS - PROJECT SUMMARY TISSUE ENGINEERED MEDICAL PRODUCTS HAVE TREMENDOUS PROMISE TO ADDRESS THE CURRENTLY IRREPARABLE EFFECTS OF NEUROTRAUMA AND/OR NEURODEGENERATIVE DISEASES. AXONOVA MEDICAL'S LEAD PRODUCT, THE TISSUE ENGINEERED NERVE GRAFT (TENG), IS A BIOACTIVE "LIVING SCAFFOLD" PROVEN TO PROMOTE RAPID NERVE REGENERATION AND FUNCTIONAL RESTORATION WHEN IMPLANTED TO REPAIR MAJOR PERIPHERAL NERVE INJURY (PNI). IMPLEMENTING LIVING NEURONAL CELLS AS THE STARTING BIOMASS, AXONOVA ROUTINELY BIOMANUFACTURES TENGS COMPRISED OF LIVING, LONG, ALIGNED AXON TRACTS THROUGH THE PROPRIETARY PROCESS OF AXON "STRETCH-GROWTH". TO DATE, TENGS HAVE BEEN SHOWN TO CONSISTENTLY PROMOTE HOST AXON REGENERATION AND IMPROVE FUNCTIONAL RECOVERY COMPARED TO CURRENT CLINICAL PRACTICES IN BOTH SMALL AND LARGE ANIMAL MODELS OF PNI, INCLUDING THE REPAIR OF 5 CM SEGMENTAL DEFECTS. IN ORDER TO MOVE TO A MANUFACTURING- COMPLIANT BIOMASS, AXONOVA HAS PARTNERED WITH REVIVICOR TO GENERATE GALSAFE TENGS USING THEIR GENETICALLY ENGINEERED PORCINE NEURONS TO MITIGATE A HOST IMMUNE RESPONSE UPON EVENTUAL TRANSPLANTATION IN HUMANS. THROUGH THE PHASE I EFFORTS, GALSAFE TENGS WERE SUCCESSFULLY STRETCH-GROWN TO CREATE PRODUCTS AT LENGTHS OF 1 CM, 3 CM, AND 5 CM WITH A HEALTH AND AXON DENSITY THAT MET OR EXCEEDED ESTABLISHED QUALITY BENCHMARKS. MOREOVER, 1 CM TENGS WERE TRANSPLANTED INTO A RODENT PNI MODEL TO DEMONSTRATE REGENERATIVE EFFICACY, REVEALING THAT GALSAFE TENGS SURVIVED AS WELL AS ACTIVELY DROVE HOST AXONAL REGENERATION VIA THE PROPRIETARY MECHANISM-OF-ACTION OF TENGS, REFERRED TO AS AXON FACILITATED AXON REGENERATION (AFAR). ALONG WITH CHOOSING A SAFE AND READILY AVAILABLE STARTING BIOMASS, OTHER PRODUCT DEVELOPMENT CHALLENGES INCLUDE BIOPRESERVATION AND QUALITY ASSURANCE CRITERIA TO ALLOW INCREASED SHELF LIFE, TRANSPORTATION, AND MAINTAINED EFFICACY OF THE PRODUCT. ACCORDINGLY, THE CURRENT PHASE II SBIR PROGRAM ADDRESSES A KEY FACET OF CLINICAL GRADE BIOMANUFACTURING, SPECIFICALLY THE VALIDATION OF AN EFFECTIVE STORAGE PROTOCOL AND RELEASE CRITERIA ENSURING PRODUCT HEALTH, STERILITY, AND POTENCY. TENGS WILL BE BIOFABRICATED FROM A CGMP-COMPLIANT CELL SOURCE (GALSAFE PORCINE NEURONS), COLD- STORED USING A CGMP-COMPLIANT PRESERVATION PROTOCOL, AND THEN TESTED IN SMALL AND LARGE ANIMAL MODELS OF PNI TO DEMONSTRATE REGENERATIVE EFFICACY. SPECIFICALLY, AXONOVA WILL SYSTEMATICALLY COMPLETE THE OBJECTIVES OF THIS PROGRAM ACROSS 3 SPECIFIC AIMS: (1) DETERMINE THE EFFICACY OF FRESH GALSAFE TENGS IN AN ESTABLISHED PORCINE PNI MODEL; (2) EFFECTIVELY BIOPRESERVE GALSAFE TENGS TO INCREASE SHELF-LIFE AND VALIDATE NON-INVASIVE RELEASE CRITERIA; AND (3) DETERMINE THE POTENCY AND EFFICACY OF BIOPRESERVED GALSAFE TENGS IN VIVO IN RODENT AND PORCINE PNI MODELS. THIS PROGRAM ADDRESSES A MAJOR CHALLENGE IN THE TRANSLATION OF NEXT-GENERATION TISSUE ENGINEERED MEDICAL PRODUCTS BY VALIDATING MANUFACTURING, STORAGE AND RELEASE CRITERIA FOR A LIVING BIOLOGICAL PRODUCT TO ENABLE EVENTUAL TESTING IN HUMANS. THE ABILITY TO STORE AND DISTRIBUTE GALSAFE TENGS AS AN "OFF-THE- SHELF" PRODUCT WILL VASTLY INCREASE COMMERCIAL POTENTIAL BY REDUCING COSTS AND EXPANDING PATIENT ACCESS, THEREBY IMPROVING RECOVERY AND QUALITY OF LIFE FOR PATIENTS SUFFERING FROM THE DEBILITATING EFFECTS OF MAJOR PNI.
$0
4/29/25
Not listed
GENERATION OF TISSUE ENGINEERED NERVE GRAFTS FROM GALSAFE PORCINE NEURONS - PROJECT SUMMARY TISSUE ENGINEERED MEDICAL PRODUCTS HAVE TREMENDOUS PROMISE TO ADDRESS THE CURRENTLY IRREPARABLE EFFECTS OF NEUROTRAUMA AND/OR NEURODEGENERATIVE DISEASES. AXONOVA MEDICAL'S LEAD PRODUCT, THE TISSUE ENGINEERED NERVE GRAFT (TENG), IS A BIOACTIVE "LIVING SCAFFOLD" PROVEN TO PROMOTE RAPID NERVE REGENERATION AND FUNCTIONAL RESTORATION WHEN IMPLANTED TO REPAIR MAJOR PERIPHERAL NERVE INJURY (PNI). IMPLEMENTING LIVING NEURONAL CELLS AS THE STARTING BIOMASS, AXONOVA ROUTINELY BIOMANUFACTURES TENGS COMPRISED OF LIVING, LONG, ALIGNED AXON TRACTS THROUGH THE PROPRIETARY PROCESS OF AXON "STRETCH-GROWTH". TO DATE, TENGS HAVE BEEN SHOWN TO CONSISTENTLY PROMOTE HOST AXON REGENERATION AND IMPROVE FUNCTIONAL RECOVERY COMPARED TO CURRENT CLINICAL PRACTICES IN BOTH SMALL AND LARGE ANIMAL MODELS OF PNI, INCLUDING THE REPAIR OF 5 CM SEGMENTAL DEFECTS. IN ORDER TO MOVE TO A MANUFACTURING- COMPLIANT BIOMASS, AXONOVA HAS PARTNERED WITH REVIVICOR TO GENERATE GALSAFE TENGS USING THEIR GENETICALLY ENGINEERED PORCINE NEURONS TO MITIGATE A HOST IMMUNE RESPONSE UPON EVENTUAL TRANSPLANTATION IN HUMANS. THROUGH THE PHASE I EFFORTS, GALSAFE TENGS WERE SUCCESSFULLY STRETCH-GROWN TO CREATE PRODUCTS AT LENGTHS OF 1 CM, 3 CM, AND 5 CM WITH A HEALTH AND AXON DENSITY THAT MET OR EXCEEDED ESTABLISHED QUALITY BENCHMARKS. MOREOVER, 1 CM TENGS WERE TRANSPLANTED INTO A RODENT PNI MODEL TO DEMONSTRATE REGENERATIVE EFFICACY, REVEALING THAT GALSAFE TENGS SURVIVED AS WELL AS ACTIVELY DROVE HOST AXONAL REGENERATION VIA THE PROPRIETARY MECHANISM-OF-ACTION OF TENGS, REFERRED TO AS AXON FACILITATED AXON REGENERATION (AFAR). ALONG WITH CHOOSING A SAFE AND READILY AVAILABLE STARTING BIOMASS, OTHER PRODUCT DEVELOPMENT CHALLENGES INCLUDE BIOPRESERVATION AND QUALITY ASSURANCE CRITERIA TO ALLOW INCREASED SHELF LIFE, TRANSPORTATION, AND MAINTAINED EFFICACY OF THE PRODUCT. ACCORDINGLY, THE CURRENT PHASE II SBIR PROGRAM ADDRESSES A KEY FACET OF CLINICAL GRADE BIOMANUFACTURING, SPECIFICALLY THE VALIDATION OF AN EFFECTIVE STORAGE PROTOCOL AND RELEASE CRITERIA ENSURING PRODUCT HEALTH, STERILITY, AND POTENCY. TENGS WILL BE BIOFABRICATED FROM A CGMP-COMPLIANT CELL SOURCE (GALSAFE PORCINE NEURONS), COLD- STORED USING A CGMP-COMPLIANT PRESERVATION PROTOCOL, AND THEN TESTED IN SMALL AND LARGE ANIMAL MODELS OF PNI TO DEMONSTRATE REGENERATIVE EFFICACY. SPECIFICALLY, AXONOVA WILL SYSTEMATICALLY COMPLETE THE OBJECTIVES OF THIS PROGRAM ACROSS 3 SPECIFIC AIMS: (1) DETERMINE THE EFFICACY OF FRESH GALSAFE TENGS IN AN ESTABLISHED PORCINE PNI MODEL; (2) EFFECTIVELY BIOPRESERVE GALSAFE TENGS TO INCREASE SHELF-LIFE AND VALIDATE NON-INVASIVE RELEASE CRITERIA; AND (3) DETERMINE THE POTENCY AND EFFICACY OF BIOPRESERVED GALSAFE TENGS IN VIVO IN RODENT AND PORCINE PNI MODELS. THIS PROGRAM ADDRESSES A MAJOR CHALLENGE IN THE TRANSLATION OF NEXT-GENERATION TISSUE ENGINEERED MEDICAL PRODUCTS BY VALIDATING MANUFACTURING, STORAGE AND RELEASE CRITERIA FOR A LIVING BIOLOGICAL PRODUCT TO ENABLE EVENTUAL TESTING IN HUMANS. THE ABILITY TO STORE AND DISTRIBUTE GALSAFE TENGS AS AN "OFF-THE- SHELF" PRODUCT WILL VASTLY INCREASE COMMERCIAL POTENTIAL BY REDUCING COSTS AND EXPANDING PATIENT ACCESS, THEREBY IMPROVING RECOVERY AND QUALITY OF LIFE FOR PATIENTS SUFFERING FROM THE DEBILITATING EFFECTS OF MAJOR PNI.
$901.0k
8/17/22
Not listed
GENERATION OF TISSUE ENGINEERED NERVE GRAFTS FROM GALSAFE PORCINE NEURONS - PROJECT SUMMARY TISSUE ENGINEERED MEDICAL PRODUCTS HAVE TREMENDOUS PROMISE TO ADDRESS THE CURRENTLY IRREPARABLE EFFECTS OF NEUROTRAUMA AND/OR NEURODEGENERATIVE DISEASES. AXONOVA MEDICAL'S LEAD PRODUCT, THE TISSUE ENGINEERED NERVE GRAFT (TENG), IS A BIOACTIVE "LIVING SCAFFOLD" PROVEN TO PROMOTE RAPID NERVE REGENERATION AND FUNCTIONAL RESTORATION WHEN IMPLANTED TO REPAIR MAJOR PERIPHERAL NERVE INJURY (PNI). IMPLEMENTING LIVING NEURONAL CELLS AS THE STARTING BIOMASS, AXONOVA ROUTINELY BIOMANUFACTURES TENGS COMPRISED OF LIVING, LONG, ALIGNED AXON TRACTS THROUGH THE PROPRIETARY PROCESS OF AXON "STRETCH-GROWTH". TO DATE, TENGS HAVE BEEN SHOWN TO CONSISTENTLY PROMOTE HOST AXON REGENERATION AND IMPROVE FUNCTIONAL RECOVERY COMPARED TO CURRENT CLINICAL PRACTICES IN BOTH SMALL AND LARGE ANIMAL MODELS OF PNI, INCLUDING THE REPAIR OF 5 CM SEGMENTAL DEFECTS. IN ORDER TO MOVE TO A MANUFACTURING- COMPLIANT BIOMASS, AXONOVA HAS PARTNERED WITH REVIVICOR TO GENERATE GALSAFE TENGS USING THEIR GENETICALLY ENGINEERED PORCINE NEURONS TO MITIGATE A HOST IMMUNE RESPONSE UPON EVENTUAL TRANSPLANTATION IN HUMANS. THROUGH THE PHASE I EFFORTS, GALSAFE TENGS WERE SUCCESSFULLY STRETCH-GROWN TO CREATE PRODUCTS AT LENGTHS OF 1 CM, 3 CM, AND 5 CM WITH A HEALTH AND AXON DENSITY THAT MET OR EXCEEDED ESTABLISHED QUALITY BENCHMARKS. MOREOVER, 1 CM TENGS WERE TRANSPLANTED INTO A RODENT PNI MODEL TO DEMONSTRATE REGENERATIVE EFFICACY, REVEALING THAT GALSAFE TENGS SURVIVED AS WELL AS ACTIVELY DROVE HOST AXONAL REGENERATION VIA THE PROPRIETARY MECHANISM-OF-ACTION OF TENGS, REFERRED TO AS AXON FACILITATED AXON REGENERATION (AFAR). ALONG WITH CHOOSING A SAFE AND READILY AVAILABLE STARTING BIOMASS, OTHER PRODUCT DEVELOPMENT CHALLENGES INCLUDE BIOPRESERVATION AND QUALITY ASSURANCE CRITERIA TO ALLOW INCREASED SHELF LIFE, TRANSPORTATION, AND MAINTAINED EFFICACY OF THE PRODUCT. ACCORDINGLY, THE CURRENT PHASE II SBIR PROGRAM ADDRESSES A KEY FACET OF CLINICAL GRADE BIOMANUFACTURING, SPECIFICALLY THE VALIDATION OF AN EFFECTIVE STORAGE PROTOCOL AND RELEASE CRITERIA ENSURING PRODUCT HEALTH, STERILITY, AND POTENCY. TENGS WILL BE BIOFABRICATED FROM A CGMP-COMPLIANT CELL SOURCE (GALSAFE PORCINE NEURONS), COLD- STORED USING A CGMP-COMPLIANT PRESERVATION PROTOCOL, AND THEN TESTED IN SMALL AND LARGE ANIMAL MODELS OF PNI TO DEMONSTRATE REGENERATIVE EFFICACY. SPECIFICALLY, AXONOVA WILL SYSTEMATICALLY COMPLETE THE OBJECTIVES OF THIS PROGRAM ACROSS 3 SPECIFIC AIMS: (1) DETERMINE THE EFFICACY OF FRESH GALSAFE TENGS IN AN ESTABLISHED PORCINE PNI MODEL; (2) EFFECTIVELY BIOPRESERVE GALSAFE TENGS TO INCREASE SHELF-LIFE AND VALIDATE NON-INVASIVE RELEASE CRITERIA; AND (3) DETERMINE THE POTENCY AND EFFICACY OF BIOPRESERVED GALSAFE TENGS IN VIVO IN RODENT AND PORCINE PNI MODELS. THIS PROGRAM ADDRESSES A MAJOR CHALLENGE IN THE TRANSLATION OF NEXT-GENERATION TISSUE ENGINEERED MEDICAL PRODUCTS BY VALIDATING MANUFACTURING, STORAGE AND RELEASE CRITERIA FOR A LIVING BIOLOGICAL PRODUCT TO ENABLE EVENTUAL TESTING IN HUMANS. THE ABILITY TO STORE AND DISTRIBUTE GALSAFE TENGS AS AN "OFF-THE- SHELF" PRODUCT WILL VASTLY INCREASE COMMERCIAL POTENTIAL BY REDUCING COSTS AND EXPANDING PATIENT ACCESS, THEREBY IMPROVING RECOVERY AND QUALITY OF LIFE FOR PATIENTS SUFFERING FROM THE DEBILITATING EFFECTS OF MAJOR PNI.
$901.0k
8/17/22
Not listed
GENERATION OF TISSUE ENGINEERED NERVE GRAFTS FROM GALSAFE PORCINE NEURONS - PROJECT SUMMARY TISSUE ENGINEERED MEDICAL PRODUCTS HAVE TREMENDOUS PROMISE TO ADDRESS THE CURRENTLY IRREPARABLE EFFECTS OF NEUROTRAUMA AND/OR NEURODEGENERATIVE DISEASES. AXONOVA MEDICAL'S LEAD PRODUCT, THE TISSUE ENGINEERED NERVE GRAFT (TENG), IS A BIOACTIVE "LIVING SCAFFOLD" PROVEN TO PROMOTE RAPID NERVE REGENERATION AND FUNCTIONAL RESTORATION WHEN IMPLANTED TO REPAIR MAJOR PERIPHERAL NERVE INJURY (PNI). IMPLEMENTING LIVING NEURONAL CELLS AS THE STARTING BIOMASS, AXONOVA ROUTINELY BIOMANUFACTURES TENGS COMPRISED OF LIVING, LONG, ALIGNED AXON TRACTS THROUGH THE PROPRIETARY PROCESS OF AXON "STRETCH-GROWTH". TO DATE, TENGS HAVE BEEN SHOWN TO CONSISTENTLY PROMOTE HOST AXON REGENERATION AND IMPROVE FUNCTIONAL RECOVERY COMPARED TO CURRENT CLINICAL PRACTICES IN BOTH SMALL AND LARGE ANIMAL MODELS OF PNI, INCLUDING THE REPAIR OF 5 CM SEGMENTAL DEFECTS. IN ORDER TO MOVE TO A MANUFACTURING- COMPLIANT BIOMASS, AXONOVA HAS PARTNERED WITH REVIVICOR TO GENERATE GALSAFE TENGS USING THEIR GENETICALLY ENGINEERED PORCINE NEURONS TO MITIGATE A HOST IMMUNE RESPONSE UPON EVENTUAL TRANSPLANTATION IN HUMANS. THROUGH THE PHASE I EFFORTS, GALSAFE TENGS WERE SUCCESSFULLY STRETCH-GROWN TO CREATE PRODUCTS AT LENGTHS OF 1 CM, 3 CM, AND 5 CM WITH A HEALTH AND AXON DENSITY THAT MET OR EXCEEDED ESTABLISHED QUALITY BENCHMARKS. MOREOVER, 1 CM TENGS WERE TRANSPLANTED INTO A RODENT PNI MODEL TO DEMONSTRATE REGENERATIVE EFFICACY, REVEALING THAT GALSAFE TENGS SURVIVED AS WELL AS ACTIVELY DROVE HOST AXONAL REGENERATION VIA THE PROPRIETARY MECHANISM-OF-ACTION OF TENGS, REFERRED TO AS AXON FACILITATED AXON REGENERATION (AFAR). ALONG WITH CHOOSING A SAFE AND READILY AVAILABLE STARTING BIOMASS, OTHER PRODUCT DEVELOPMENT CHALLENGES INCLUDE BIOPRESERVATION AND QUALITY ASSURANCE CRITERIA TO ALLOW INCREASED SHELF LIFE, TRANSPORTATION, AND MAINTAINED EFFICACY OF THE PRODUCT. ACCORDINGLY, THE CURRENT PHASE II SBIR PROGRAM ADDRESSES A KEY FACET OF CLINICAL GRADE BIOMANUFACTURING, SPECIFICALLY THE VALIDATION OF AN EFFECTIVE STORAGE PROTOCOL AND RELEASE CRITERIA ENSURING PRODUCT HEALTH, STERILITY, AND POTENCY. TENGS WILL BE BIOFABRICATED FROM A CGMP-COMPLIANT CELL SOURCE (GALSAFE PORCINE NEURONS), COLD- STORED USING A CGMP-COMPLIANT PRESERVATION PROTOCOL, AND THEN TESTED IN SMALL AND LARGE ANIMAL MODELS OF PNI TO DEMONSTRATE REGENERATIVE EFFICACY. SPECIFICALLY, AXONOVA WILL SYSTEMATICALLY COMPLETE THE OBJECTIVES OF THIS PROGRAM ACROSS 3 SPECIFIC AIMS: (1) DETERMINE THE EFFICACY OF FRESH GALSAFE TENGS IN AN ESTABLISHED PORCINE PNI MODEL; (2) EFFECTIVELY BIOPRESERVE GALSAFE TENGS TO INCREASE SHELF-LIFE AND VALIDATE NON-INVASIVE RELEASE CRITERIA; AND (3) DETERMINE THE POTENCY AND EFFICACY OF BIOPRESERVED GALSAFE TENGS IN VIVO IN RODENT AND PORCINE PNI MODELS. THIS PROGRAM ADDRESSES A MAJOR CHALLENGE IN THE TRANSLATION OF NEXT-GENERATION TISSUE ENGINEERED MEDICAL PRODUCTS BY VALIDATING MANUFACTURING, STORAGE AND RELEASE CRITERIA FOR A LIVING BIOLOGICAL PRODUCT TO ENABLE EVENTUAL TESTING IN HUMANS. THE ABILITY TO STORE AND DISTRIBUTE GALSAFE TENGS AS AN "OFF-THE- SHELF" PRODUCT WILL VASTLY INCREASE COMMERCIAL POTENTIAL BY REDUCING COSTS AND EXPANDING PATIENT ACCESS, THEREBY IMPROVING RECOVERY AND QUALITY OF LIFE FOR PATIENTS SUFFERING FROM THE DEBILITATING EFFECTS OF MAJOR PNI.
$934.1k
8/23/21
Not listed
GENERATION OF TISSUE ENGINEERED NERVE GRAFTS FROM GALSAFE PORCINE NEURONS - PROJECT SUMMARY TISSUE ENGINEERED MEDICAL PRODUCTS HAVE TREMENDOUS PROMISE TO ADDRESS THE CURRENTLY IRREPARABLE EFFECTS OF NEUROTRAUMA AND/OR NEURODEGENERATIVE DISEASES. AXONOVA MEDICAL'S LEAD PRODUCT, THE TISSUE ENGINEERED NERVE GRAFT (TENG), IS A BIOACTIVE "LIVING SCAFFOLD" PROVEN TO PROMOTE RAPID NERVE REGENERATION AND FUNCTIONAL RESTORATION WHEN IMPLANTED TO REPAIR MAJOR PERIPHERAL NERVE INJURY (PNI). IMPLEMENTING LIVING NEURONAL CELLS AS THE STARTING BIOMASS, AXONOVA ROUTINELY BIOMANUFACTURES TENGS COMPRISED OF LIVING, LONG, ALIGNED AXON TRACTS THROUGH THE PROPRIETARY PROCESS OF AXON "STRETCH-GROWTH". TO DATE, TENGS HAVE BEEN SHOWN TO CONSISTENTLY PROMOTE HOST AXON REGENERATION AND IMPROVE FUNCTIONAL RECOVERY COMPARED TO CURRENT CLINICAL PRACTICES IN BOTH SMALL AND LARGE ANIMAL MODELS OF PNI, INCLUDING THE REPAIR OF 5 CM SEGMENTAL DEFECTS. IN ORDER TO MOVE TO A MANUFACTURING- COMPLIANT BIOMASS, AXONOVA HAS PARTNERED WITH REVIVICOR TO GENERATE GALSAFE TENGS USING THEIR GENETICALLY ENGINEERED PORCINE NEURONS TO MITIGATE A HOST IMMUNE RESPONSE UPON EVENTUAL TRANSPLANTATION IN HUMANS. THROUGH THE PHASE I EFFORTS, GALSAFE TENGS WERE SUCCESSFULLY STRETCH-GROWN TO CREATE PRODUCTS AT LENGTHS OF 1 CM, 3 CM, AND 5 CM WITH A HEALTH AND AXON DENSITY THAT MET OR EXCEEDED ESTABLISHED QUALITY BENCHMARKS. MOREOVER, 1 CM TENGS WERE TRANSPLANTED INTO A RODENT PNI MODEL TO DEMONSTRATE REGENERATIVE EFFICACY, REVEALING THAT GALSAFE TENGS SURVIVED AS WELL AS ACTIVELY DROVE HOST AXONAL REGENERATION VIA THE PROPRIETARY MECHANISM-OF-ACTION OF TENGS, REFERRED TO AS AXON FACILITATED AXON REGENERATION (AFAR). ALONG WITH CHOOSING A SAFE AND READILY AVAILABLE STARTING BIOMASS, OTHER PRODUCT DEVELOPMENT CHALLENGES INCLUDE BIOPRESERVATION AND QUALITY ASSURANCE CRITERIA TO ALLOW INCREASED SHELF LIFE, TRANSPORTATION, AND MAINTAINED EFFICACY OF THE PRODUCT. ACCORDINGLY, THE CURRENT PHASE II SBIR PROGRAM ADDRESSES A KEY FACET OF CLINICAL GRADE BIOMANUFACTURING, SPECIFICALLY THE VALIDATION OF AN EFFECTIVE STORAGE PROTOCOL AND RELEASE CRITERIA ENSURING PRODUCT HEALTH, STERILITY, AND POTENCY. TENGS WILL BE BIOFABRICATED FROM A CGMP-COMPLIANT CELL SOURCE (GALSAFE PORCINE NEURONS), COLD- STORED USING A CGMP-COMPLIANT PRESERVATION PROTOCOL, AND THEN TESTED IN SMALL AND LARGE ANIMAL MODELS OF PNI TO DEMONSTRATE REGENERATIVE EFFICACY. SPECIFICALLY, AXONOVA WILL SYSTEMATICALLY COMPLETE THE OBJECTIVES OF THIS PROGRAM ACROSS 3 SPECIFIC AIMS: (1) DETERMINE THE EFFICACY OF FRESH GALSAFE TENGS IN AN ESTABLISHED PORCINE PNI MODEL; (2) EFFECTIVELY BIOPRESERVE GALSAFE TENGS TO INCREASE SHELF-LIFE AND VALIDATE NON-INVASIVE RELEASE CRITERIA; AND (3) DETERMINE THE POTENCY AND EFFICACY OF BIOPRESERVED GALSAFE TENGS IN VIVO IN RODENT AND PORCINE PNI MODELS. THIS PROGRAM ADDRESSES A MAJOR CHALLENGE IN THE TRANSLATION OF NEXT-GENERATION TISSUE ENGINEERED MEDICAL PRODUCTS BY VALIDATING MANUFACTURING, STORAGE AND RELEASE CRITERIA FOR A LIVING BIOLOGICAL PRODUCT TO ENABLE EVENTUAL TESTING IN HUMANS. THE ABILITY TO STORE AND DISTRIBUTE GALSAFE TENGS AS AN "OFF-THE- SHELF" PRODUCT WILL VASTLY INCREASE COMMERCIAL POTENTIAL BY REDUCING COSTS AND EXPANDING PATIENT ACCESS, THEREBY IMPROVING RECOVERY AND QUALITY OF LIFE FOR PATIENTS SUFFERING FROM THE DEBILITATING EFFECTS OF MAJOR PNI.
$934.1k
8/23/21